NASH Accelerated Approval: US FDA Remains Confident In Pathway For Liver Disease
Executive Summary
A two-day workshop on potential biomarkers in NASH provided a forum for US FDA officials to offer implicit reassurance to drug developers: the agency stands behind its guidance on Accelerated Approval for the liver disease, despite the rejection of the first application seeking to use that approach.
You may also be interested in...
Accelerated Approvals: Conversions Still Outweigh Withdrawals, But Takeda’s Exkivity Brings 2023’s Pull Count To Six
US FDA’s Oncologic Drugs Advisory Committee will convene in November for a ‘general discussion about delayed confirmatory trials’ and the ‘continued optimization of the accelerated approval process.’
Italy’s Alfasigma Comes Calling After Intercept’s Cruel Summer
The Bologna-based firm is looking to grow its presence in the US as well as in gastrointestinal and liver disease as it acquires Intercept, which received a second rejection for its NASH drug OCA in June.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.